Prostate cancer

GU010

PARALLEL PHASE III RANDOMIZED TRIALS OF GENOMIC-RISK STRATIFIED UNFAVORABLE INTERMEDIATE RISK PROSTATE CANCER: DE-INTENSIFICATION AND INTENSIFICATION CLINICAL TRIAL EVALUATION (GUIDANCE)

Trial overview

Topic

NRG-GU010

Disease

Prostate cancer

Description

To determine whether men with National Comprehensive Cancer Network (NCCN) unfavorable intermediate risk (UIR) prostate cancer and lower Decipher genomic risk (Decipher score < 0.40) treated with RT alone instead of 6 months ADT + RT experience non-inferior rate of distant metastasis.

Contact

Michigan

Maria Pappas

Florida

Peggy Mouradian

Physicians

John Vito Antonucci

MD

Radiation Oncologist

Madison Heights (Radiation oncology) +3

Alvaro A. Martinez

MD, FACR, FABS, FASTRO

Radiation Oncologist

Pontiac (Radiation oncology) +4

Michael I. Ghilezan

MD, PhD

Radiation Oncologist

Pontiac (Radiation oncology) +3

Frank A. Vicini

MD, FACR, FASTRO, FABS

Radiation Oncologist

Farmington Hills (Radiation oncology) +2

Eduardo B. Fernandez

MD, PhD, FACRO, FASTRO

Radiation Oncologist

Aventura (Radiation oncology) +3

Christopher T. Chen

MD, FACRO

Radiation Oncologist

Pembroke Pines (Radiation oncology) +1

Patrick M. Francke

MD, FACRO

Radiation Oncologist

Myrtle Beach (Radiation oncology)